The invention relates to a pharmaceutical combination which comprises (a) a phosphosnositide 3-kinase inhibitor compound and (b) an insulin sensitivity enhancer compound for the treatment of a proliferative disease, especially a solid tumor disease a pharmaceutical composition comprising such a combination the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use and to a method of treatment of a warm-blooded animal, especially a human.
